Today: The Research Analysts Set Expectations for Merck & Co.’s Q3 2016 Earnings (MRK)

The Research Analysts Set Expectations for Merck & Co.’s Q3 2016 Earnings (MRK)

Merck & Co. (NYSE:MRK) – Stock analysts at Jefferies Group issued their Q3 2016 earnings per share (EPS) estimates for Merck & Co. in a report issued on Thursday. Jefferies Group analyst J. Holford anticipates that the brokerage will post earnings of $0.98 per share for the quarter. Jefferies Group currently has a “Hold” rating and a $56.00 price objective on the stock. Jefferies Group also issued estimates for Merck & Co.’s FY2017 earnings at $4.16 EPS.

Merck & Co. (NYSE:MRK) last released its earnings results on Friday, July 29th. The company reported $0.93 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.02. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The firm earned $9.84 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the prior year, the firm earned $0.86 EPS. The company’s revenue was up .6% compared to the same quarter last year.

MRK has been the topic of several other research reports. Vetr raised shares of Merck & Co. from a “sell” rating to a “buy” rating and set a $62.26 target price on the stock in a report on Monday, July 4th. Argus reissued a “buy” rating and issued a $65.00 target price on shares of Merck & Co. in a report on Wednesday, September 14th. Bank of America Corp. raised shares of Merck & Co. from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $57.00 to $70.00 in a report on Thursday. Zacks Investment Research raised shares of Merck & Co. from a “hold” rating to a “buy” rating and set a $70.00 target price on the stock in a report on Friday. Finally, Leerink Swann reissued a “hold” rating and issued a $58.00 target price on shares of Merck & Co. in a report on Thursday, July 14th. Twelve analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of €65.05 ($72.28).

Merck & Co. (NYSE:MRK) traded down 0.376% on Friday, hitting $62.275. 5,485,535 shares of the stock were exchanged. The stock has a market cap of $172.20 billion, a price-to-earnings ratio of 34.161 and a beta of 0.68. Merck & Co. has a 12 month low of $47.97 and a 12 month high of $64.86. The company has a 50-day moving average of $62.57 and a 200-day moving average of $58.63.

The company also recently announced a quarterly dividend, which was paid on Friday, October 7th. Stockholders of record on Thursday, September 15th were paid a $0.46 dividend. This represents a $1.84 annualized dividend and a dividend yield of 2.94%. The ex-dividend date of this dividend was Tuesday, September 13th. Merck & Co.’s dividend payout ratio is currently 101.10%.

In other news, EVP Clark Golestani sold 3,000 shares of the stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of €63.03 ($70.03), for a total value of €189,090.00 ($210,100.00). The sale was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Kenneth C. Frazier sold 392,000 shares of the stock in a transaction on Friday, August 5th. The shares were sold at an average price of €61.81 ($68.68), for a total transaction of €24,229,520.00 ($26,921,688.89). Following the completion of the sale, the chairman now directly owns 760,877 shares in the company, valued at approximately €47,029,807.37 ($52,255,341.52). The disclosure for this sale can be found here. 0.05% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in MRK. Acrospire Investment Management LLC increased its stake in shares of Merck & Co. by 5.9% in the second quarter. Acrospire Investment Management LLC now owns 1,800 shares of the company’s stock valued at $104,000 after buying an additional 100 shares in the last quarter. Roble Belko & Company Inc increased its stake in shares of Merck & Co. by 124.7% in the second quarter. Roble Belko & Company Inc now owns 1,802 shares of the company’s stock valued at $104,000 after buying an additional 1,000 shares in the last quarter. Americafirst Capital Management LLC purchased a new stake in shares of Merck & Co. during the second quarter valued at $115,000. First New York Securities LLC NY purchased a new stake in shares of Merck & Co. during the second quarter valued at $121,000. Finally, NewSquare Capital LLC increased its stake in shares of Merck & Co. by 14.2% in the second quarter. NewSquare Capital LLC now owns 2,104 shares of the company’s stock valued at $121,000 after buying an additional 261 shares in the last quarter. 72.93% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co. Company Profile

Related posts

Leave a Comment